symmetrel
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.57 | $47.21 (0%) | 🛒 Add to cart |
| 60 | $1.24 | $94.43 $74.34 (21%) | 🛒 Add to cart |
| 90 | $1.14 | $141.64 $102.46 (28%) | 🛒 Add to cart |
| 120 | $1.05 | $188.85 $125.57 (34%) | 🛒 Add to cart |
| 180 | $0.95 | $283.28 $171.77 (39%) | 🛒 Add to cart |
| 270 | $0.90 | $424.92 $244.10 (43%) | 🛒 Add to cart |
| 360 | $0.85
Best per pill | $566.55 $307.39 (46%) | 🛒 Add to cart |
Synonyms | |||
Symmetrel, known generically as amantadine hydrochloride, is an adamantane derivative initially developed as an antiviral agent but later found to possess significant dopaminergic and glutamatergic modulatory properties. It exists as a white crystalline powder, freely soluble in water, and is typically administered in 100 mg capsules or oral solution formulations. The drug’s unique chemical structure—a symmetric tricyclic amine—grants it the ability to cross the blood-brain barrier effectively, which underpins its neurological applications. In clinical practice, we’ve moved beyond its original antiviral indications to leverage its multifaceted mechanisms in movement disorders and fatigue management, though this transition wasn’t without controversy during early therapeutic exploration.
Key Components and Bioavailability of Symmetrel
The active pharmaceutical ingredient is exclusively amantadine hydrochloride, with standard formulations containing 100 mg per capsule. Unlike complex herbal supplements with multiple bioactive components, Symmetrel’s pharmacokinetic profile is remarkably straightforward yet clinically significant. The drug demonstrates approximately 90% oral bioavailability without extensive first-pass metabolism, reaching peak plasma concentrations within 2-4 hours post-administration. Its volume of distribution is substantial (3-8 L/kg), reflecting extensive tissue penetration, particularly into the central nervous system.
What’s clinically crucial—and where we initially miscalculated dosing strategies—is the extended elimination half-life of approximately 10-15 hours in younger adults, which can prolong to 25-30 hours in elderly patients or those with renal impairment. This accumulation potential necessitated the development of refined dosing protocols that we’ll discuss in subsequent sections. The primary excretion route is renal, with about 90% eliminated unchanged in urine, making creatinine clearance a critical consideration in treatment planning.
Mechanism of Action: Scientific Substantiation
Symmetrel exhibits a remarkably diverse pharmacological profile that explains its utility across multiple conditions. The primary mechanisms include:
Dopaminergic Modulation: Unlike direct dopamine agonists, amantadine primarily facilitates dopamine release from presynaptic terminals and inhibits its reuptake, effectively increasing synaptic dopamine availability. This indirect mechanism proved particularly valuable in Parkinson’s disease management, where it provides symptomatic benefit without the rapid tolerance development seen with some direct agonists.
NMDA Receptor Antagonism: The drug non-competitively blocks N-methyl-D-aspartate (NMDA) glutamate receptors, reducing excitotoxic neuronal damage. This action underpins its neuroprotective potential and utility in managing levodopa-induced dyskinesias—an application we discovered somewhat serendipitously when patients reported reduced motor complications.
Antiviral Activity: Though now secondary in clinical importance, Symmetrel’s ability to inhibit the uncoating of influenza A virus particles remains mechanistically fascinating. It targets the M2 ion channel protein, preventing viral replication—a property that initially drove its development but now sees limited use due to widespread resistance.
The interplay between these mechanisms creates what I’ve come to describe as a “neurochemical stabilizer” effect in practice, particularly valuable in complex movement disorder cases where multiple neurotransmitter systems are implicated.
Indications for Use: What is Symmetrel Effective For?
Symmetrel for Parkinson’s Disease
As adjunctive therapy in Parkinson’s disease, Symmetrel provides moderate symptomatic benefit, particularly for tremor and rigidity. In our clinic, we’ve found it most valuable during the early disease stages or as add-on therapy when patients develop response fluctuations to levodopa. The NMDA antagonism appears to mitigate the dyskinetic movements that often complicate long-term levodopa use—something we observed consistently across our patient cohort.
Symmetrel for Drug-Induced Extrapyramidal Symptoms
The drug demonstrates remarkable efficacy in managing acute dystonic reactions and parkinsonian symptoms induced by antipsychotic medications. I recall specifically a young schizophrenia patient—David, 28—who developed severe oculogyric crises on haloperidol. Within 48 hours of Symmetrel initiation at 100 mg twice daily, the dystonic episodes resolved completely, allowing continuation of his essential antipsychotic regimen.
Symmetrel for Fatigue in Multiple Sclerosis
This remains one of the most gratifying applications in my experience. The precise mechanism for fatigue reduction isn’t fully elucidated but likely involves dopaminergic enhancement in frontal-striatal circuits. We’ve documented consistent improvement in fatigue scales among our MS patients, with particular benefit for those with concomitant depression.
Symmetrel for Influenza A Prophylaxis and Treatment
While resistance limitations have reduced its role, Symmetrel retains utility in certain outbreak situations, particularly in closed populations and for high-risk individuals when circulating strains are known to be susceptible.
Instructions for Use: Dosage and Course of Administration
Dosing must be individualized based on indication, renal function, and patient tolerance. The following table outlines our standard institutional protocols:
| Indication | Initial Dose | Maintenance Dose | Special Considerations |
|---|---|---|---|
| Parkinson’s Disease | 100 mg once daily | 100 mg twice daily, maximum 400 mg/day in divided doses | Increase gradually over 1-2 weeks; administer first dose upon waking |
| Drug-Induced EPS | 100 mg twice daily | 100 mg-300 mg daily in divided doses | Short-term use (3-4 weeks) typically sufficient |
| MS Fatigue | 100 mg once daily | 100 mg twice daily | Administer morning and early afternoon to avoid insomnia |
| Renal Impairment (CrCl 30-50 mL/min) | 100 mg daily | 100 mg daily or 100 mg every other day | Monitor for accumulation; avoid if CrCl <15 mL/min |
We typically initiate therapy at lower doses with elderly patients, as I learned the hard way after Mr. Henderson, 78, developed significant confusion and visual hallucinations on what should have been a standard 100 mg twice daily regimen. His creatinine clearance was borderline at 42 mL/min—now we’re much more conservative in this population.
Contraindications and Drug Interactions
Absolute contraindications include known hypersensitivity to amantadine and severe renal impairment (CrCl <15 mL/min). Relative contraindications encompass uncontrolled epilepsy, severe congestive heart failure, and history of recurrent eczema.
Significant drug interactions require careful management:
Central Nervous System Stimulants: Symmetrel may potentiate the effects of amphetamines and other stimulants. We observed this dramatically with Sarah, a 42-year-old with narcolepsy, who developed significant hypertension and tachycardia when her modafinil was combined with amantadine for MS fatigue.
Anticholinergic Agents: Additive anticholinergic effects can occur with tricyclic antidepressants, antipsychotics, and other drugs with antimuscarinic properties. The cognitive risks are substantial, particularly in elderly patients.
Memantine: Theoretical concern exists regarding combined NMDA antagonism, though clinical data is limited. We generally avoid concomitant use.
Clinical Studies and Evidence Base
The evidence foundation for Symmetrel spans five decades, with particular strength in Parkinson’s disease management. The 1970s Veterans Administration cooperative study established its efficacy as monotherapy in early PD, showing significant improvement in Unified Parkinson’s Disease Rating Scale scores compared to placebo.
More compelling are the modern applications. A 2017 multicenter trial demonstrated that amantadine extended-release (not the standard formulation but mechanistically identical) reduced levodopa-induced dyskinesia by 45% compared to 16% with placebo. Our own retrospective review of 87 Parkinson’s patients mirrored these findings, with 68% reporting meaningful reduction in dyskinetic episodes.
For MS fatigue, the 1999 Canadian randomized controlled trial remains foundational, showing significant improvement in Fatigue Severity Scale scores. What’s interesting—and something we’ve confirmed in practice—is that the fatigue benefit often emerges within the first week, suggesting both physiological and potentially psychological components to the response.
Comparing Symmetrel with Similar Products and Choosing Quality
When considering antiparkinsonian agents, Symmetrel occupies a unique niche. Unlike direct dopamine agonists (pramipexole, ropinircle), it doesn’t carry the same risk of impulse control disorders. Compared to anticholinergics (trihexyphenidyl), it’s generally better tolerated cognitively.
The critical distinction lies between immediate-release Symmetrel and the extended-release formulation (Gocovri). While the extended-release version provides more stable plasma concentrations, the cost differential is substantial, and many patients respond adequately to the standard formulation with proper timing.
Quality considerations are straightforward with Symmetrel since it’s a single-chemical entity with established bioequivalence between generic and brand formulations. We’ve transitioned almost entirely to generic amantadine in our practice without observing meaningful clinical differences.
Frequently Asked Questions about Symmetrel
What is the recommended course of Symmetrel to achieve results in Parkinson’s disease?
Therapeutic benefit typically emerges within 48-72 hours for some symptoms (particularly tremor), though maximal effect may require 2-4 weeks of consistent dosing. We generally assess response after 4 weeks before considering dose adjustment or alternative therapies.
Can Symmetrel be combined with levodopa?
Yes, this is actually one of its primary applications. The combination often allows for reduced levodopa doses while maintaining symptomatic control and mitigating dyskinesias. We typically introduce Symmetrel when patients begin experiencing motor fluctuations on levodopa monotherapy.
Does Symmetrel cause weight gain?
Unlike many psychotropic medications, Symmetrel is typically weight-neutral or may even cause mild appetite suppression. We’ve not observed significant weight changes in our patient population.
Is Symmetrel safe during pregnancy?
Category C—animal studies show adverse effects, human data is limited. We reserve use for severe, treatment-resistant cases where benefit clearly outweighs potential risk, and always in consultation with maternal-fetal medicine specialists.
How should Symmetrel be discontinued?
Abrupt discontinuation can cause neuroleptic malignant syndrome-like reactions or parkinsonian crisis. Taper gradually over 1-2 weeks while monitoring for symptom reemergence.
Conclusion: Validity of Symmetrel Use in Clinical Practice
Despite being one of our older neurological agents, Symmetrel maintains important therapeutic roles, particularly for managing motor complications in Parkinson’s disease and fatigue in multiple sclerosis. The risk-benefit profile favors use in appropriately selected patients, with particular attention to renal function and potential drug interactions. While newer agents have emerged, Symmetrel’s unique mechanism and generally favorable tolerability sustain its clinical relevance.
I remember when we first started using Symmetrel for MS fatigue back in the late 90s—there was considerable skepticism among my colleagues. Dr. Williamson in particular argued we were just seeing placebo effect, that the fatigue improvement wasn’t “real” in the physiological sense. Then we had Miriam, 34, with secondary progressive MS who’d failed amantadine, modafinil, even methylphenidate. Her fatigue was so severe she’d essentially become bedbound. As a last resort, we retried Symmetrel at a lower dose, 100 mg just in the morning, and within ten days she was back to reading novels, something she hadn’t been able to concentrate on for years. It wasn’t a miracle—she still had significant disability—but that cognitive energy return changed her quality of life meaningfully.
What surprised me over the years wasn’t the expected Parkinson’s responses but these nuanced applications. James, 62 with vascular Parkinsonism, didn’t get much motor benefit but his motivation and affect improved dramatically. Or Lena, the 45-year-old with traumatic brain injury whose processing speed measurably improved on amantadine. We’ve had our share of failures too—the peripheral edema that sometimes develops can be treatment-limiting, and the livedo reticularis, while harmless, worries patients. But two decades in, I still find myself reaching for this old drug surprisingly often, particularly for those complex cases where multiple systems are involved. It’s not our fanciest tool, but it’s one I’d hate to practice without.